Cardiogenic shock (MONDO:0800175; Orphanet:97292) is a rare cardiac condition characterized by severely decreased cardiac output, hypoperfusion, and end-organ dysfunction in the presence of adequate intravascular volume. The clinical presentation is variable, ranging from subtle hemodynamic alterations to overt cardiovascular collapse. The condition reflects a state in which the heart is unable to maintain sufficient perfusion to meet systemic metabolic demands. Commonly described features include dyspnea, crackles, elevated jugular venous pressure, altered mental state, abnormal pulse pressure, oliguria, cold extremities, and increased serum lactate levels.

The most frequently observed clinical features include abnormal electrocardiographic findings, hypotension, abnormal left ventricular function, and low-output congestive heart failure, each reported at very high frequency. Frequently observed features include congestive heart failure, myocardial infarction, cardiac arrest, dyspnea, reduced consciousness, impaired myocardial contractility, arrhythmia, crackles, elevated jugular venous pressure, low pulse pressure, increased pulmonary capillary wedge pressure, oliguria, orthopnea, hypoxemia, cyanosis, and edema. Features reported at occasional frequency include confusion, mitral regurgitation, metabolic acidosis, increased circulating lactate concentration, and hepatomegaly.

The pathophysiological basis of cardiogenic shock involves severely diminished cardiac output insufficient to maintain end-organ perfusion despite adequate intravascular volume. Myocardial infarction and congestive heart failure are listed as frequently associated conditions in the clinical data for this condition. Impaired myocardial contractility and arrhythmias contribute to the hemodynamic compromise that defines the disorder. The distinction from other shock states rests on the presence of a cardiac rather than a volume-deficient or distributive etiology. No germline gene associations are listed in this packet, consistent with the acquired nature of the condition.

Diagnosis is supported by a constellation of hemodynamic and clinical findings. Abnormal electrocardiographic tracings are a very frequent finding, alongside evidence of abnormal left ventricular function and low-output cardiac failure. Elevated jugular venous pressure, increased pulmonary capillary wedge pressure, and hypotension are frequently observed hemodynamic indicators. End-organ hypoperfusion is reflected clinically by oliguria and reduced consciousness. Metabolic acidosis and elevated serum lactate concentration are occasionally present and indicate tissue-level oxygen debt resulting from diminished cardiac output.

No pharmacological agents are listed as approved by regulatory authorities specifically for cardiogenic shock in this packet. Three compounds hold orphan drug designation without approval: alfimeprase (Niche Therapeutics, LLC), Hemoximer—a pyridoxalated hemoglobin polyoxyethylene conjugate (Apex Bioscience, Inc.)—and tilarginine acetate (Arginox Pharmaceuticals, Inc.). These designations reflect investigational interest in novel therapeutic strategies. Numerous clinical trials, including studies of mechanical circulatory support devices and pharmacological combinations, are ongoing and are described further in the Research section.

Cardiogenic shock is associated with significant clinical severity. The presentation can range from subtle hemodynamic compromise to overt cardiovascular collapse, the latter representing the most severe end of the spectrum. End-organ involvement—including oliguria, reduced consciousness, metabolic acidosis, and elevated circulating lactate—reflects systemic hypoperfusion of varying degree and indicates the breadth of multisystem impact that may accompany this condition.

Ten clinical trials addressing cardiogenic shock are active or recently recruiting. Registry-based studies include the Naples Federico II Intensive Cardiac Care Unit Registry (Federico II University), the Cardiogenic Shock Working Group Registry (Tufts Medical Center), and the SWISS Circulatory Support Registry (Insel Gruppe AG). Interventional studies are examining mechanical circulatory support strategies, including comparisons of early left ventricular unloading by Impella versus intra-aortic balloon pump (University Hospital Montpellier) and an intra-aortic balloon counterpulsation compliance study (Thomas Jefferson University). The Pilot Italian Cardiogenic Shock Initiative (Fondazione GISE Onlus) represents a multicenter national effort. A Phase 2 trial at Rigshospitalet (Denmark) is evaluating low-dose dobutamine combined with single-dose tocilizumab in acute myocardial infarction at high risk of cardiogenic shock. Additional studies are examining digital out-of-hospital management and sedation protocols in critically ill cardiac patients.